Clinical Trials Browser

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT05982522 2025-04-30

IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2 Not yet recruiting

72 enrolled

Other solid neoplasm

Solid Tumor

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Phase 1/2 Recruiting

120 enrolled

Thoracic

Small Cell Lung Cancer Extensive Stage

Clinical Trials

KontRASt-01

KontRASt-R

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

TOUCH

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

TALENT

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

IN10018 Combination Therapy in Previously-treated Solid Tumors

IN10018 Combination Therapy in Treatment-naïve ES-SCLC